

23. An antibody fusion protein as defined one in any one of claims 1 to 15 or a composition as defined in claim 21 or 22 for use in therapy.
24. An antibody fusion protein as defined in any one of claims 1 to 15 or a composition as defined in claim 21 or 22, for use in the treatment of an autoimmune disease, such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.
25. Use of a therapeutically effective amount of an antibody or binding fragment thereof as defined in any one of claims 1 to 15 or a composition as defined in claim 21 or claim 22 in the manufacture of a medicament for the treatment of an autoimmune disease.
26. The use according to claim 25, wherein the autoimmune disease is selected from the group consisting of myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.